Is Starpharma a T/O target for......., page-2

Keith is always upbeat with Starpharma and writes a reasonable case for investing in the company.
However in this instance his research is behind the times although I don't know when the article was written.
Firstly he is unaware that the Dep Gemcitibane trial has been canned and secondly he didn't recognise that JF herself admitted that the Dep Docetaxal trial has lost it's gloss due to advancements with immunotherapy.
Apart from that we all live in hope that big pharma will save our bacon with an acceptable TO offer well before our grandkids inherit our SPL holdings